GNH USA

Europe — EMA

Imcivree (Setmelanotide)

GNH USA supplies Imcivree (Setmelanotide), a melanocortin‑4 receptor agonist for obesity linked to POMC, PCSK1, LEPR deficiencies and rare syndromes.

Setmelanotide

Request sourcing

1
Pack/s

What is Setmelanotide?

Setmelanotide, the active ingredient in Imcivree, is a melanocortin 4 receptor (MC4R) agonist presented as a 1 mg/mL subcutaneous injection solution for subcutaneous use. It is indicated for the treatment of obesity associated with specific genetic deficiencies, including proopiomelanocortin (POMC) deficiency, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, leptin receptor (LEPR) deficiency, Bardet‑Biedl syndrome, and Alström syndrome.

GNH USA supplies Imcivree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

What is Setmelanotide used for?

Imcivree targets rare genetic forms of obesity by modulating the melanocortin pathway. It is prescribed for the following conditions: - Obesity due to POMC deficiency: reduces appetite and promotes weight loss in patients with this genetic form of obesity. - Obesity due to PCSK1 deficiency: helps control body weight by enhancing energy expenditure. - Obesity due to LEPR deficiency: improves satiety signaling and supports weight reduction. - Obesity associated with Bardet‑Biedl syndrome: assists in managing excess weight linked to this ciliopathy. - Obesity associated with Alström syndrome: contributes to weight management in this multisystem disorder.

What are the side effects of Setmelanotide?

Imcivree may cause a range of adverse reactions. Monitoring and reporting are essential for patient safety.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Nausea: feeling of queasiness that may occur after dosing. - Headache: mild to moderate head discomfort. - Hyperpigmentation: darkening of the skin, particularly around the injection area.

Serious or Rare Side Effects: - Severe injection site infection: signs of cellulitis or abscess requiring medical attention. - Hypersensitivity reactions: rash, itching, or anaphylaxis in rare cases. - Marked hyperpigmentation: extensive skin darkening that may be disfiguring.

What precautions apply to Setmelanotide?

Before initiating Imcivree, clinicians should consider several safety aspects. - Pregnancy: safety not established; avoid unless potential benefit justifies the risk. - Breastfeeding: unknown effects; weigh maternal benefit against potential infant exposure. - Renal impairment: monitor renal function as clearance may be affected. - Cardiovascular disease: observe blood pressure and heart rate during therapy. - Concomitant melanocortin agonists: avoid due to additive pharmacologic activity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Setmelanotide interact with?

Imcivree can interact with other medicines; awareness of interaction severity guides management.

Major Interactions (Avoid): - Other MC4R agonists: additive effect may increase risk of adverse events. - Immunosuppressive agents: may impair wound healing at injection sites.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: monitor blood pressure for potential changes. - Antidiabetic medications: observe glucose levels as weight loss can affect glycemic control. - Live vaccines: consider timing as immune modulation could alter vaccine response.

Frequently asked questions

What is Imcivree used for?+
Imcivree is prescribed for the management of obesity in patients with rare genetic conditions that affect the melanocortin pathway, such as POMC, PCSK1, or LEPR deficiencies, as well as Bardet‑Biedl and Alström syndromes. By targeting these specific pathways, the medication helps reduce appetite and promote weight loss in affected individuals.
How does setmelanotide work?+
Setmelanotide is a selective agonist of the melanocortin‑4 receptor (MC4R) located in the hypothalamus. Activation of MC4R enhances satiety signals and increases basal energy expenditure, which together lower food intake and support weight reduction in patients whose genetic defects impair normal MC4R signaling.
What is the usual dose of Imcivree?+
The dose of Imcivree is individualized by the prescribing clinician based on the patient’s genetic diagnosis, body weight, and response to therapy. The medication is supplied as a prefilled pen delivering 0.5 mg per subcutaneous injection, and the prescriber determines the appropriate dosing schedule and titration plan.
Is Imcivree safe in pregnancy or breastfeeding?+
Safety data for Imcivree during pregnancy and lactation are limited. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.
How do I order Imcivree from GNH USA?+
To request Imcivree, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details—including cold‑chain handling if needed—and assist with import documentation.
How does Imcivree compare with other anti‑obesity agents?+
Unlike conventional anti‑obesity drugs that act broadly on appetite or metabolism, Imcivree specifically targets the MC4R pathway and is approved only for genetically defined forms of obesity. This precision makes it effective where other agents have limited impact, but it also restricts its use to patients with confirmed MC4R‑related genetic defects.
How should Imcivree be stored and handled?+
Imcivree must be stored refrigerated between 2 °C and 8 °C. Keep the prefilled pen in its original packaging, protect it from light, and avoid freezing or shaking. If the product is inadvertently exposed to temperatures outside this range, discard it and obtain a new supply.
How is Imcivree administered?+
Imcivree is given as a subcutaneous injection using a prefilled pen that delivers a fixed 0.5 mg dose. The injection is typically administered into the abdomen, thigh, or upper arm, rotating sites to reduce local irritation. Administration technique and site rotation are explained by the prescribing clinician.
What are the most serious risks to watch for with Imcivree?+
Serious risks include severe injection‑site infections, hypersensitivity reactions such as anaphylaxis, and marked hyperpigmentation that can be disfiguring. Patients should be instructed to report any signs of infection, rash, swelling, or unexpected skin darkening promptly, and clinicians should monitor for these events throughout therapy.
Who should not use Imcivree?+
Imcivree is contraindicated in individuals with known hypersensitivity to setmelanotide or any excipients in the formulation. It should also be avoided in patients receiving other MC4R agonists due to the risk of additive effects, and in those where the benefit–risk profile is unfavorable, such as uncontrolled severe infections or unstable cardiovascular disease.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Setmelanotide
Route
Subcutaneous Use
Manufacturer
Rhythm Pharmaceuticals Netherlands B.V.
Origin
EU

Related products

Imcivree

Imcivree

Setmelanotide

Rhythm Pharmaceuticals Netherlands B.V.
EU
Imcivree

Imcivree

Setmelanotide

Rhythm Pharmaceuticals Netherlands B.V.
EU
Imcivree

Imcivree

Setmelanotide

Rhythm Pharmaceuticals Netherlands B.V.
EU